Interestingly, pharmacological inhibition of sphingosine kinases 1 was shown to reverse obesity-inflammation in skeletal muscles of obese mice [88] and to reduce pancreatic lesions in spontaneously diabetic rats [89], therefore legitimating the use of such approaches to modulate both EV lipid composition and obesity-related disorders. This evidence concerns the gene SPHK1 and obesity disorder.